Thus, the DNA-repair defect associated with BRCA1/2 loss may predispose these cells to the kind of mutation that leads to reversion. It is not clear whether treatment with DNA-damaging agents, ...

Transcriptomic and protein expression analysis of helicase antigen (HAGE) in triple negative breast cancer (TNBC) as a novel prognostic and predictive biomarker. This is an ASCO Meeting Abstract from ...

Mutations in the BRCA1 gene that are either inherited (germline) or acquired (somatic) might not be key to the initiation of prostate cancer, as previously thought, suggests the first study of its ...

Doctors have long recognized that women with mutations in two particular genes – BRCA1 and BRCA2 – have a higher risk of breast and ovarian cancer. Now they are starting to figure out which ...

Nearly half of breast cancer patients carrying the BRCA1 gene mutation experience a complete pathological response (pCR) – the disappearance of all evidence of disease from the breast tissue and ...

The report, published online Monday in the Journal of Clinical Oncology, studied nearly 5,800 women with specific genetic mutations called BRCA1 and BRCA2. Researchers found that women with BRCA1 ...

Jen Culton learned she had the BRCA1 gene mutation after her older sister's breast-cancer diagnosis. She decided to have two of her daughters tested; one daughter also has the BRCA1 gene mutation.

The BRCA1 and BRCA2 genes protect against breast and ovarian cancer, and a mutation of either gene increases the risk of developing cancer. An estimated 1 in 350 women have aBRCA1 or BRCA2 mutation.

Researchers have discovered a link between the BRCA1 gene mutation and lower levels of a hormone that is an indicator of the number of eggs left in a woman's ovaries, according to research ...

BRCA1/2 mutation carriers exhibited a more pronounced pathologic complete response rate, especially with carboplatin. The study predates the immunotherapy era, necessitating contextual interpretation ...